IPX066: a novel carbidopa–levodopa extended-release formulation

References

• Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson’s disease: scientific rationale and clinical implications. Lancet Neurol.5, 677–687 (2006).
   PubMed Web of Science ®Google Scholar
• Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin. Pharmacokinet.41, 261–309 (2002).
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N. Engl. J. Med.342, 1484–1491 (2000).
   PubMed Web of Science ®Google Scholar
• Holloway RG, Shoulson I, Fahn S et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61, 1044–1053 (2004).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch. Neurol.62, 905–910 (2005).
   PubMed Web of Science ®Google Scholar
• Hauser RA. Levodopa: past, present, and future. Eur. Neurol.62, 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Hammerstad JP, Woodward WR, Nutt JG, Gancher ST, Block GA, Cyhan G. Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients. Clin. Neuropharmacol.17, 429–434 (1994).
   PubMedGoogle Scholar
• Hauser RA. Levodopa/carbidopa/entacapone (Stalevo). Neurology62(1, Suppl. 1), S64–S71 (2004).
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Jennings D, Lyons KE et al. Pharmacokinetic–pharmacodynamic crossover comparison of two levodopa extension strategies. Mov. Disord.24, 1319–1324 (2009).
   PubMed Web of Science ®Google Scholar
• Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson’s disease. Expert Opin. Pharmacother.8, 657–664 (2007).
   PubMed Web of Science ®Google Scholar
• Hauser RA. Future treatments for Parkinson’s disease: surfing the PD pipeline. Int. J. Neurosci.121(Suppl. 2), 53–62 (2011).
   PubMed Web of Science ®Google Scholar
• Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov. Disord.17, 1235–1241 (2002).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Ellenbogen AL, Metman LV et al. Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson’s disease. Mov. Disord.26, 2246–2252 (2011).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Nausieda P, Ondo W et al. Double-blind, controlled trial of IPX066, a novel carbidopa–levodopa extended-release formulation, in advanced Parkinson’s disease (ADVANCE-PD trial). Presented at: Movement Disorder Society Meeting 2011. Toronto, ON, Canada, 5–7 June 2011 (Abstract LB9).
   Google Scholar
• Pahwa R, Ellenbogen A, Jankovic J, Hauser R, Fahn S; Clinical Team at Impax Pharmaceuticals. Efficacy and safety of IPX066, a new carbidopa–levodopa (CD–LD) extended-release formulation, in LD-naive early Parkinson’s disease (APEX-PD trial). Mov. Disord.26(Suppl. 2), S137 (2011).
   Google Scholar
• Hauser RA, Deckers F, Lehert P. Parkinson’s disease home diary: further validation and implications for clinical trials. Mov. Disord.19, 1409–1413 (2004).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Auinger P; Parkinson Study Group. Determination of minimal clinically important change in early and advanced Parkinson’s disease. Mov. Disord.26, 813–818 (2011).
   PubMed Web of Science ®Google Scholar
• Stocchi F, Rascol O, Kieburtz K et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann. Neurol.68, 18–27 (2010). Erratum in: Ann. Neurol.68, 412–413 (2010).
   PubMed Web of Science ®Google Scholar
• Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch. Neurol.63, 1756–1760 (2006).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R et al.; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med.361, 1268–1278 (2009). Erratum in: N. Engl. J. Med.364, 1882 (2011).
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ; TEMPO Open-label Study Group. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson’s disease. Mov. Disord.24, 564–573 (2009).
   PubMed Web of Science ®Google Scholar
• Pålhagen S, Heinonen E, Hägglund J, Kaugesaar T, Mäki-Ikola O, Palm R; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology66, 1200–1206 (2006).
   PubMed Web of Science ®Google Scholar